NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results
Initial Phase 1/2 data presented at the 63rd American Society of Hematology (ASH) Annual Meeting and ExpositionPhase 1/2 study of NEXI-002 as a monotherapy...
Source: globenewswire.com